Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.46 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6902158 | 1.00 | CYP3A4 (0.65) | CYP3A4HDAC1HDAC6HDAC4CYP2D6 | |
| SCHEMBL30515122 | 0.90 | CYP3A4 (0.73) | CYP3A4CYP2D6 | |
| SCHEMBL4312545 | 0.90 | CYP3A4 (0.73) | CYP3A4CYP2D6 | |
| SCHEMBL173030 | 0.90 | CYP3A4 (0.73) | CYP3A4CYP2D6 | |
| SCHEMBL1032335 | 0.90 | CYP3A4 (0.73) | CYP3A4CYP2D6 | |
| SCHEMBL7262136 | 0.88 | CYP3A4 (0.64) | CYP3A4CYP2D6HPRT1 | |
| SCHEMBL9177152 | 0.88 | CYP3A4 (0.64) | CYP3A4CYP2D6HSP90AA1HSP90AB1HPRT1 | |
| SCHEMBL9177212 | 0.88 | CYP3A4 (0.64) | CYP3A4CYP2D6HSP90AA1HSP90AB1HPRT1 | |
| SCHEMBL9176435 | 0.87 | CYP3A4 (0.49) | CYP3A4HDAC1HDAC6HDAC4HSP90AA1 | |
| SCHEMBL9177023 | 0.87 | CYP3A4 (0.49) | CYP3A4HDAC1HDAC6HDAC4HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3561272-B2 | — | — | 2004-09-02 | — | — | JP | claimed |
| EP-0654037-B1 | ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS | ACAD OF SCIENCE CZECH REPUBLIC (CZ) | 1999-05-12 | — | — | EP | claimed |
| EP-0654037-A1 | ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1995-05-24 | — | — | EP | claimed |
| WO-1994003467-A2 | ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1994-02-17 | — | — | WO | claimed |
| EP-3578563-B1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | GERON CORP (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20200283461-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2020-09-10 | — | — | US | disclosed |
| US-10562926-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2020-02-18 | — | — | US | disclosed |
| EP-2794624-B1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | GERON CORP (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20190106447-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2019-04-11 | — | — | US | disclosed |
| US-10035814-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035814-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170233419-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2017-08-17 | — | — | US | disclosed |
| US-20170233419-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2017-08-17 | — | — | US | disclosed |
| US-9593137-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593137-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2017-03-14 | — | — | US | disclosed |
| US-20150299232-A1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2015-10-22 | — | — | US | disclosed |
| US-20150299232-A1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2015-10-22 | — | — | US | disclosed |
| US-6479673-B1 | Antiretroviral enantiomeric nucleotide analogs | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2002-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562926-B2 | Guanine analogs as telomerase substrates and telomere length affectors | TERT, POT1, TERF2 | CYP3A4 4353/4885HDAC1 3013/4885HDAC6 3064/4885 |
| US-20170233419-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | TERT, POT1, TERF2 | CYP3A4 4353/4885HDAC1 3013/4885HDAC6 3064/4885 |
| US-10035814-B2 | Guanine analogs as telomerase substrates and telomere length affectors | TERT, POT1, TERF2 | CYP3A4 4353/4885HDAC1 3013/4885HDAC6 3064/4885 |
| US-20200283461-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | TERT, POT1, TERF2 | CYP3A4 4353/4885HDAC1 3013/4885HDAC6 3064/4885 |
| US-20150299232-A1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | TERT, POT1, TERF2 | CYP3A4 4402/4885HDAC1 3064/4885HDAC6 3170/4885 |
| US-20190106447-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | TERT, POT1, TERF2 | CYP3A4 4353/4885HDAC1 3013/4885HDAC6 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.